Key Highlights
- 8.81% is the indicated pre-market gain for Basel Medical Group Ltd (NASDAQ:BMGL) on November 18, 2026, lifting the price to USD 0.3531 from a calculated prior close of USD 0.3245, a calculated move of USD 0.0286.
- 6 million units at USD 1.33 each were priced in the registered direct offering announced on October 9, 2026, producing about USD 7.98 million in gross proceeds and about USD 7.28 million in net proceeds.
- 7,582,111 ordinary shares were expected outstanding after that offering, up from 1,582,111 before it, a calculated increase of 379.2%, before counting 6 million common warrants and the pre-funded Warrant structure.
- 5 years is the exercise period for the common warrants issued with the October 9, 2026 offering, which include a zero-cash exercise option that could issue up to 6 million additional shares.
What Moved Basel Medical Group Ltd (NASDAQ:BMGL) in Pre-Market Trading on November 18, 2026 (+USD 0.0286, +8.81%)
The indicated pre-market price for Basel Medical Group Ltd (NASDAQ:BMGL) is USD 0.3531 on November 18, 2026, a pre-market move of +8.81%. The calculated prior close, the November 17, 2026 regular-session close, is USD 0.3245 (USD 0.3531 divided by 1.0881), and the calculated USD move is +USD 0.0286. Using about 7,582,111 shares expected after the October 2026 offering, the calculated market Capitalization is about USD 2.68 million, though the current share count was not corroborated.
The Rationale: No Same-Day Catalyst Identified After the October Offering for Basel Medical Group Ltd (NASDAQ:BMGL)
No catalyst for the November 18, 2026 move was identified in published coverage. As general context, sub-dollar micro-caps often move on thin float and follow-through after sharp prior-session swings. The latest identified company event is the registered direct offering announced on October 9, 2026 by the Singapore-based healthcare provider, which runs clinics serving mainly corporate clients in construction, marine and oil and gas. It comprised 6 million units priced at USD 1.33, each with one ordinary share or pre-funded warrant plus a common warrant exercisable for five years at 110% of the offering price. The company also disclosed a Nasdaq delinquency notification on December 1, 2025, because its fiscal 2025 Annual Report initially lacked the auditor's opinion, and said trading was not affected.
Valuation, Liquidity and Risks for Basel Medical Group Ltd (NASDAQ:BMGL)
Dilution is the central risk. Shares rose from 1,582,111 to about 7,582,111 after the offering, a calculated increase of 379.2%, with 6 million common warrants and a zero-cash exercise option that could add up to 6 million more. The calculated market capitalization of about USD 2.68 million is well under USD 100 million, so this is a nano-cap where liquidity is thin and moves of 8% or more can occur without news. The indicated price is a calculated 73.5% below the USD 1.33 offering price. Fiscal 2025 Revenue rose 12.6% to SGD 11.3 million in published coverage, but current cash, profit and Debt were not found.
Where Things Stand
Basel Medical Group Ltd (NASDAQ:BMGL) is indicated up 8.81% in pre-market trading on November 18, 2026, at USD 0.3531, a calculated gain of USD 0.0286 from a prior close of USD 0.3245. No specific catalyst was identified in published coverage. The latest identified corporate action is the October 9, 2026 offering of 6 million units at USD 1.33, which lifted the share count to about 7,582,111. Dilution, warrants and a calculated market capitalization near USD 2.68 million are key risks, and pre-market moves can reverse at the 9:30 a.m. ET open. This is not Investment advice.






Please wait processing your request...